"By bringing together two experts in the ADC value chain, biopharmaceutical companies should benefit from shorter timelines and less complexity, allowing them to focus their efforts on drug discovery, ...

Drug Substance manufacturing is a critical component of pharmaceutical production, requiring precise processes, rigorous quality control, and innovative solutions to overcome various challenges. From ...

Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, ...

Global High Potency API CDMOs Market OverviewThe global high potency active pharmaceutical ingredient (HPAPI) CDMOs market is ...

The global contract development and manufacturing organization announced March 23 it completed initial engineering studies for an expanded facility in Charles City, Iowa. Groundbreaking for the new ...

Axplora, a German CDMO that specializes in specialty active pharmaceutical ingredients for small molecules and antibody-drug conjugates, will shell out $60 million to expand its Farmabios ...

Scheduled for August 2025 completion, the initial $2-billion phase included construction of a 1-million-sq-ft complex with two drug substance manufacturing buildings, each containing four 20,000-liter ...

Eli Lilly has revealed the location of the first of four large-scale manufacturing facilities that it plans to build in the U.S. The company has selected Goochland County, Virginia, as the site of a ...

While the United Kingdom feted President Trump in his second state visit, GSK said Wednesday it will spend $30 billion over the next five years to build new manufacturing and research facilities ...

India hosts more active pharmaceutical ingredient (API) manufacturing sites that are compliant with the U.S. Food and Drug Administration than any country outside the U.S., and it produces more ...